TNBC – BiotechReality – Information Intelligence System for Biopharma

Trodelvy (sacituzumab govitecan-hziy), a drug by Gilead Sciences, has demonstrated notable progress in a Phase 3 clinical trial for patients with a type of breast cancer that is challenging to treat. According to the ASCENT-03 study, patients with metastatic triple-negative breast cancer (TNBC) undergoing their first line of treatment had a 38% lower chance of disease progression or death when using Trodelvy as opposed to chemotherapy. A new standard of care for a patient population with few treatment options may be provided by the study's findings, which are being hailed as potentially "practice-changing." The median progression-free survival (PFS) for trial participants who received Trodelvy was 9.7 months, while the median PFS for those who received chemotherapy was 6.9 months. Patients with metastatic TNBC who are ineligible for immunotherapy face an especially poor prognosis, with limited treatment options and fast disease progression, The ability of sacituzumab govitecan to significantly delay death and progression could represent the first major treatment advance for this patient population in the 20 years since TNBC was defined, marking an historic shift and establishing a potential new standard of care. Dr. Javier Cortés Read More: Gliead Releases the Results of Phase 3 ASCENT-04/KEYNOTE-D19 Trials Shows Positive Effect for Combinational Use of Trodelvy® Plus Keytruda® The duration of response (DOR) was significantly longer for those receiving Trodelvy treatment, even though the objective response rate (ORR) was comparable for the two groups (48% for Trodelvy and 46% for chemotherapy). Compared to 7.2 months for chemotherapy, the median DOR for trodelvy was 12.2 months. Trodelvy's safety profile in the ASCENT-03 study was in line with earlier research, and no novel safety indicators were found. The most frequent severe side effects were anaemia and neutropenia for chemotherapy, and diarrhoea and neutropenia for Trodelvy. Crucially, the Trodelvy group experienced fewer treatment discontinuations as a result of adverse events than the chemotherapy group (4% vs. 12%). About 15% of all breast cancers are triple-negative breast cancers, which are an aggressive type of the disease. Women of colour and younger women are more likely to experience it. For these patients, the results of the ASCENT-03 study provide fresh hope. Gilead will continue to monitor the patients even though the study's overall survival data is not yet complete. Yet, the ASCENT-03 trial's encouraging outcomes mark a major advancement in the management of metastatic triple-negative breast cancer. Information: Gilead Sciences Last Modified:

Tag: TNBC

Gilead’s Trodelvy Shows Significant Promise in Treating Aggressive Breast Cancer

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment